Typically on days like this shares gap higher at the open and then gradually decline and close below the open (though possibly above the previous day's close.) Buying on scientific news seldom drives share price to higher sustainable levels. That applies to ROSG and virtually every other development stage company.
Don't you just hate it when you are wrong? Patents don't generate revenue. In fact, to make use of them you have to invest more cash. If anything, you'll see this as justification for yet another secondary.